A pharma company recently received US FDA approval for Wyost and Jubbonti, the first FDA-approved denosumab biosimilars.
About Denosumab:
- It is designed to address primary and secondary bone loss, such as osteoporosis, and cancer-related skeletal events.
About the Wyost and Jubbonti:
- Wyost is approved to prevent skeletal-related events in patients with multiple myeloma and bone metastases, treat giant cell tumor of bone, and manage hypercalcemia of malignancy.
- Jubbonti targets osteoporosis treatment in postmenopausal women and older men, as well as increasing bone mass in patients with certain types of cancer or those at high risk for fracture.
About the Biosimilars:
- Biosimilars, closely mirroring the structure and function of biologics, are known as “similar biologics” in India, offering the same safety and effectiveness as their reference products, and are produced from similar sources like living cells or microorganisms.
- They are used to treat a wide range of conditions, including chronic skin diseases, chronic bowel diseases, diabetes, arthritis, and kidney conditions.
- Despite being derived from living sources, which may cause minor differences between batches, both biosimilars and original biologics maintain consistent strength and dosage.
Ref:Source
| UPSC IAS Preparation Resources | |
| Current Affairs Analysis | Topperspedia |
| GS Shots | Simply Explained |
| Daily Flash Cards | Daily Quiz |